research use only

Selpercatinib (LOXO-292) RET Inhibitor

Cat.No.S8781

Selpercatinib (LOXO-292, ARRY-192) is a potent and specific RET (c-RET) inhibitor with IC50 values of 1 nM, 2 nM, 2 nM, 4 nM, 2 nM, 2 nM for WT RET, RET V804M, RET V804L, RET A883F, RET M918T and RET S891A respectively.
Selpercatinib (LOXO-292) c-RET inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 525.60

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 525.60 Formula

C29H31N7O3

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2152628-33-4 -- Storage of Stock Solutions

Synonyms ARRY-192 Smiles CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O

Solubility

In vitro
Batch:

DMSO : 25 mg/mL (47.56 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
RET wt [1]
(Cell-free assay)
1 nM
RET V804M [1]
(Cell-free assay)
2 nM
RET V804L [1]
(Cell-free assay)
2 nM
RET M918T [1]
(Cell-free assay)
2 nM
RET S891A [1]
(Cell-free assay)
2 nM
RET A883F [1]
(Cell-free assay)
4 nM
In vitro

Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor.

References

Applications

Methods Biomarkers Images PMID
Western blot pRET / Flag / cPARP / Actin S8781-WB-1 33161056

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05324124 Completed
Healthy
Loxo Oncology Inc.|Eli Lilly and Company
April 19 2022 Phase 1
NCT05136404 Completed
Healthy
Loxo Oncology Inc.|Eli Lilly and Company
December 3 2021 Phase 1
NCT05089019 Completed
Healthy
Loxo Oncology Inc.|Eli Lilly and Company
October 29 2021 Phase 1
NCT04782076 Completed
Healthy
Loxo Oncology Inc.|Eli Lilly and Company
March 5 2021 Phase 1
NCT04280081 Active not recruiting
Solid Tumor|Medullary Thyroid Cancer
Loxo Oncology Inc.|Eli Lilly and Company
March 16 2020 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map